Jordyn A Lopes, Nicole E Garnier, Yanlong Pei, Jacob G E Yates, Elena S B Campbell, Melanie M Goens, Madison E Hughes, Amira D Rghei, Brenna A Y Stevens, Matthew M Guilleman, Brad Thompson, Cezar M Khursigara, Leonardo Susta, Sarah K Wootton
Pseudomonas aeruginosa poses a significant threat to immunocompromised individuals and those with cystic fibrosis. Treatment relies on antibiotics, but persistent infections occur due to intrinsic and acquired resistance of P. aeruginosa towards multiple classes of antibiotics. To date, there are no licensed vaccines for this pathogen, prompting the urgent need for novel treatment approaches to combat P. aeruginosa infection and persistence. Here we validated AAV vectored immunoprophylaxis as a strategy to generate long-term plasma and mucosal expression of highly protective monoclonal antibodies (mAbs) targeting the exopolysaccharide Psl (Cam-003) and the PcrV (V2L2MD) component of the type-III secretion system injectosome either as single mAbs or together as a bispecific mAb (MEDI3902) in a mouse model...
April 27, 2024: Gene Therapy